HSP90AA1 and cancer: Administrations of Hsp90 inhibitors via circulation, including tanespimycin (17-AAG), retaspimycin hydrochloride (IPI-504), ganetespib (STA-9090), BIIB021 (CNF 2024), luminespib (NVP-AUY922), and onalespib (AT13387) have all caused similar DLTs in patients with various cancers, including advanced GISTs and as result none advanced to US FDA approval, despite some trial reached phase III clinical evaluation.61